Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 243Squamous Cell Carcinoma of Head and Neck 137Melanoma 137Parkinson Disease 4, Autosomal Dominant Lewy Body 119Neoplasm Metastasis 105Triple Negative Breast Neoplasms 96Neoplasms 90Lung Neoplasms 88Breast Neoplasms 79Colorectal Neoplasms 70Carcinoma, Renal Cell 69Head and Neck Neoplasms 59Urinary Bladder Neoplasms 50Stomach Neoplasms 48Ovarian Neoplasms 46Endometrial Neoplasms 45Carcinoma, Transitional Cell 44Carcinoma, Hepatocellular 35Uterine Cervical Neoplasms 34Pancreatic Neoplasms 34Esophageal Neoplasms 27Recurrence 25Prostatic Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma 25Sarcoma 24Brain Neoplasms 23Glioblastoma 22Hodgkin Disease 19Cholangiocarcinoma 19

Interventions

pembrolizumab 4aldesleukin 3Cisplatin 3lenvatinib 2Surveys and Questionnaires 2Specimen Handling 2Paclitaxel 2Nivolumab 2Magnetic Resonance Spectroscopy 2Adoptive Transfer 2zimberelimab 1trastuzumab deruxtecan 1tivozanib 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1entinostat 1dostarlimab 1cemiplimab 1bintrafusp alfa protein, human 1belzutifan 1atezolizumab 1Therapeutic Touch 1Taxes 1Standard of Care 1Sonazoid 1Respiratory Function Tests 1Radiotherapy 1Radiation 1Prochlorperazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Vulvar Neoplasms × pembrolizumab × 1 year × Clear all
NCT05903833 2026-05-11

PIERCE

AGO Research GmbH

Phase 2 Recruiting
42 enrolled
Gynecologic

Vulvar Neoplasms

NCT04430699 2026-05-05

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
24 enrolled
Gynecologic

Vulvar Neoplasms

NCT07290894 2026-04-02

MITO VULVA-01

National Cancer Institute, Naples

Phase 2 Recruiting
80 enrolled
Gynecologic

Vulvar Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡